

B2 32  
36

(Amended) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass

- a. a therapeutically effective amount of a first compound, said first compound being droloxifene, raloxifene, tamoxifen or idoxifene; and
- b. a therapeutically effective amount of a second compound, said second compound being sodium fluoride.

Please cancel claims 43 and 44 without prejudice or disclaimer.

Please amend claims 45 and 46 as follows:

B3

39  
45

(Amended) A kit containing a treatment for a condition which presents with low bone mass comprising:

- a. a therapeutically effective amount of droloxifene, raloxifene, tamoxifen or idoxifene and a pharmaceutically acceptable carrier in a first unit dosage form;
- b. a therapeutically effective amount of a sodium fluoride and a pharmaceutically acceptable carrier in a second unit dosage form; and
- c. container means for containing said first and second dosage forms.

40  
46

(Amended) A pharmaceutical composition comprising:

- a. a therapeutically effective amount of a first compound, said first compound being

Serial No.: 09/736,051

PC9344B (121\*254)

B3  
Centa

Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-  
-naphthalene-2-ol;

(-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-  
naphthalene-2-ol;

Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-  
naphthalene-2-ol;

Cis-1-[6'-pyrrolidinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-  
tetrahydroaphthalene;

1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-  
tetrahydroisoquinoline;

Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-  
tetrahydro-naphthalene-2-ol; or

1-(4'-Pyrrolidinoethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-  
tetrahydroisoquinoline; and

- b. a therapeutically effective amount of a second compound, said second compound  
being sodium fluoride, a parathyroid hormone, or growth hormone.

---

Please cancel claim 51 without prejudice or disclaimer.

Please amend claim 52 as follows:

45

52:

(Amended) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass

- a. a therapeutically effective amount of a first compound, said first compound being
- Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
  - (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
  - Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
  - Cis-1-[6'-pyrrolidinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydro-naphthalene;
  - 1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;
  - Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; or
  - 1-(4'-Pyrrolidinoethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline; and

B

Serial No.: 09/736,051

- B<sup>4</sup> cert
- b. a therapeutically effective amount of a second compound, said second compound being sodium fluoride, a parathyroid hormone, or growth hormone.

Please cancel claims 56, 63, and 64 without prejudice or disclaimer.

Please amend claims 65 and 73 as follows:

B<sup>5</sup> 55 65. (Amended) A kit containing a treatment for a condition which presents with low bone mass comprising:

- a. a therapeutically effective amount of
- Cis*-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
- (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
- Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
- Cis*-1-[6'-pyrrolidinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydrohaphthalene;
- 1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;
- Cis*-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; or

Serial No.: 09/736,051

PC9344B (121\*254)

B<sup>5</sup> *Contd*  
1-(4'-Pyrrolidinoethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline

- b. and a pharmaceutically acceptable carrier in a first unit dosage form;  
a therapeutically effective amount of sodium fluoride, a parathyroid hormone, or growth hormone and a pharmaceutically acceptable carrier in a second unit dosage form; and

c. container means for containing said first and second dosage forms.

B<sup>6</sup> *73*  
*Sub C1*  
(Amended) A pharmaceutical composition comprising:

- a. a therapeutically effective amount of a first compound, said first compound being raloxifene, tamoxifen or idoxifene; and  
b. a therapeutically effective amount of a second compound, said second compound being a parathyroid hormone or growth hormone.

Please cancel claim 78 without prejudice or disclaimer.

Please amend claim 79 as follows:

B<sup>7</sup> *79*  
*Sub C2*  
(Amended) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass

- a. a therapeutically effective amount of a first compound, said first compound being raloxifene, tamoxifen or idoxifene; and  
b. a therapeutically effective amount of a second compound, said second compound

Serial No.: 09/736,051

B7  
contd.

being a parathyroid hormone or growth hormone.

Please cancel claims 83, 90, and 91 without prejudice or disclaimer.

B8

92. (Amended) A kit containing a treatment for a condition which presents with low bone mass comprising:

- 3/13
- a therapeutically effective amount of raloxifene, tamoxifen or idoxifene; and a pharmaceutically acceptable carrier in a first unit dosage form;
  - a therapeutically effective amount of a parathyroid hormone or growth hormone and a pharmaceutically acceptable carrier in a second unit dosage form; and
  - container means for containing said first and second dosage forms.

Please add new claims 93-108, as follows:

B9

93. (New) A combination that comprises an estrogen agonist/antagonist and a growth hormone secretagogue.

94. 74 (New) The combination of claim 93, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt.

95. 75 (New) The combination of claim 93, wherein the estrogen agonist/antagonist is raloxifene or a pharmaceutically acceptable salt thereof.

96. 76 (New) The combination of claim 93, wherein the estrogen agonist/antagonist is (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmaceutically acceptable salt thereof.

Serial No.: 09/736,051

77  
97. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 93.

78  
98. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 94.

79  
99. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 95.

80  
100. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 96.

81  
101. (New) The method of claim 97 wherein the condition is osteoporosis.

82  
102. (New) A pharmaceutical composition comprising an estrogen agonist/antagonist, a growth hormone secretagogue, and a pharmaceutically acceptable carrier.

83  
103. (New) The composition of claim 102, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt.

84  
104. (New) The composition of claim 102, wherein the estrogen agonist/antagonist is raloxifene or a pharmaceutically acceptable salt thereof.

Serial No.: 09/736,051

85  
105.

*B9*  
*with*

(New) The composition of claim ~~102~~ <sup>82</sup>, wherein the estrogen agonist/antagonist is (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof.

86  
106.

(New) A process for making a pharmaceutical composition comprising combining an estrogen agonist/antagonist, a growth hormone secretagogue, and a pharmaceutically acceptable carrier.

87  
107.

<sup>86</sup>  
(New) The process of claim ~~106~~, wherein the estrogen agonist/antagonist is raloxifene, (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmaceutically acceptable salt thereof.

88  
108.

<sup>86</sup>  
(New) The process of claim ~~106~~, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt.